Nuvalent, Inc.
Targeted small molecule therapeutics for cancer
- Sector
- Biotech
- Headquarters
- CAMBRIDGE, MA
- Founded
- 2017
- Latest Form D
- $135M, May 2021
- Total capital
- $135M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $135M
- 1 Form D · last May 2021
- 66 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 7
- 33 pending · first 2023
- Rank in peer group#213 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$135M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#213 · top 15%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Alex Porter BalcomExecutive OfficerNamed in SEC Form D filings
- Andrew Porter HackDirectorNamed in SEC Form D filings
- Cameron Porter WheelerDirectorNamed in SEC Form D filings
- Gary Porter GillilandDirectorNamed in SEC Form D filings
- Joseph Porter PearlbergDirectorNamed in SEC Form D filings
- Matthew Porter ShairDirectorNamed in SEC Form D filings
Show all 8 people
- R. Porter JamesExecutive Officer, DirectorNamed in SEC Form D filings
- Robert Porter JacksonDirectorNamed in SEC Form D filings
What it has protected
USPTO · 7 granted of 40- GrantedSolid Forms, Pharmaceutical Compositions And Preparation Of Heteroaromatic Macrocyclic Ether CompoundsUSPTOUS 12,630,560
- PendingHeteroaromatic Macrocyclic Ether Chemotherapeutic AgentsUSPTOApplication 19053900
- PendingMethods Of Treating Solid Tumor Using (19R)-5-CHLORO-3-ETHYL-16-FLUORO-10,19-DIMETHYL-20-OXA-3,4,10,11,23-PENTAAZAPENTACYCLO[19.3.1.02,6.08,12.013,18]PENTACOSA-1(24),2(6),4,8,11,13,15,17,21(25),22-DECAEN-22-AMINEUSPTOApplication 18854274
Show all 40 patent records
- Solid Forms, Pharmaceutical Compositions And Preparation Of Heteroaromatic Macrocyclic Ether CompoundsMay 19, 2026 · US 12,630,560Granted
- Heteroaromatic Macrocyclic Ether Chemotherapeutic AgentsDec 18, 2025 · Application 19053900Pending
- Methods Of Treating Solid Tumor Using (19R)-5-CHLORO-3-ETHYL-16-FLUORO-10,19-DIMETHYL-20-OXA-3,4,10,11,23-PENTAAZAPENTACYCLO[19.3.1.02,6.08,12.013,18]PENTACOSA-1(24),2(6),4,8,11,13,15,17,21(25),22-DECAEN-22-AMINENov 6, 2025 · Application 18854274Pending
- Heteroaromatic Macrocyclic Ether Chemotherapeutic AgentsOct 23, 2025 · Application 19122102Pending
- Heteroaromatic Macrocyclic Ether Chemotherapeutic AgentsApr 15, 2025 · US 12,275,742Granted
- Methods Of Treating Solid Tumor Using Heteroaromatic Macrocyclic Ether CompoundsDec 5, 2024 · Application 18697204Pending
- Heteroaromatic Macrocyclic Ether Chemotherapeutic AgentsOct 24, 2024 · Application 18745209Pending
- Amino-substituted Heterocycles For Treating Cancers With Egfr MutationsOct 3, 2024 · Application 18665844Pending
- Heteroaromatic Macrocyclic Ether Chemotherapeutic AgentsAug 6, 2024 · US 12,054,498Granted
- Solid Forms, Pharmaceutical Compositions And Preparation Of Heteroaromatic Macrocyclic Ether CompoundsJul 23, 2024 · US 12,043,626Granted
- Amino-substituted Heteroaryls For Treating Cancers With Egfr MutationsJul 16, 2024 · US 12,037,346Granted
- Solid Forms, Pharmaceutical Compositions And Preparation Of Heteroaromatic Macrocyclic Ether CompoundsOct 12, 2023 · Application 18131581Pending
- Heteroaromatic Macrocyclic Ether Chemotherapeutic AgentsJun 6, 2023 · US 11,667,649Granted
- Heteroaromatic Macrocyclic Ether Chemotherapeutic AgentsJan 3, 2023 · US 11,542,278Granted
- Solid Forms, Pharmaceutical Compositions And Preparation Of Heteroaromatic Macrocyclic Ether CompoundsApplication PCTUS2023065434Pending
- Heteroaromatic Macrocyclic Ether Chemotherapeutic AgentsApplication 63417368Pending
- Solid Forms, Pharmaceutical Compositions And Preparation Of Heteroaromatic Macrocyclic Ether CompoundsApplication PCTUS2022077323Pending
- Heteroaromatic Macrocyclic Ether CompoundsApplication 19103138Pending
- Heteroaromatic Macrocyclic Ether Compounds And Isotopologues ThereofApplication 19103121Pending
- Methods Of Treating Solid Tumor Using Heteroaromatic Macrocyclic Ether CompoundsApplication PCTUS2022077364Pending
- Methods Of Treating Solid Tumor Using Heteroaromatic Macrocyclic Ether CompoundsApplication 63376962Pending
- Heteroaromatic Macrocyclic Ether Compounds And Isotopologues ThereofApplication 63397495Pending
- Heteroaromatic Macrocyclic Ether CompoundsApplication 63397674Pending
- Methods Of Treating Solid Tumor Using Heteroaromatic Macrocyclic Ether CompoundsApplication 63357309Pending
- Methods Of Treating Solid Tumor Using Heteroaromatic Macrocyclic Ether CompoundsApplication 63356702Pending
- Amino-substituted Heterocycles For Treating Cancers With Egfr MutationsApplication PCTUS2022024334Pending
- Solid Forms, Pharmaceutical Compositions And Preparation Of Heteroaromatic Macrocyclic Ether CompoundsApplication 63328609Pending
- Methods Of Treating Solid Tumor Using Heteroaromatic Macrocyclic Ether CompoundsApplication 63328620Pending
- Amino-substituted Heterocycles For Treating Cancers With Egfr MutationsApplication 63292605Pending
- Methods Of Treating Solid Tumor Using Heteroaromatic Macrocyclic Ether CompoundsApplication 63251536Pending
- Solid Forms, Pharmaceutical Compositions And Preparation Of Heteroaromatic Macrocyclic Ether CompoundsApplication 63251514Pending
- Amino-substituted Heterocycles For Treating Cancers With Egfr MutationsApplication 63242837Pending
- Amino-Substituted Heterocycles for Treating Cancers with EGFR MutationsApplication 63239089Pending
- Heteroaromatic Macrocyclic Ether Chemotherapeutic AgentsApplication PCTUS2021030842Pending
- Heteroaromatic Macrocyclic Ether Chemotherapeutic AgentsApplication PCTUS2021030940Pending
- Amino-Substituted Heterocycles for Treating Cancers with EGFR MutationsApplication 63174177Pending
- Heteroaromatic Macrocyclic Ether Chemotherapeutic AgentsApplication 63125733Pending
- Heteroaromatic Macrocyclic Ether Chemotherapeutic AgentsApplication 63125747Pending
- Heteroaromatic Macrocyclic Ether Chemotherapeutic AgentsApplication 63060331Pending
- Heteroaromatic Macrocyclic Ether Compounds And Isotopologues ThereofApplication 19522472Pending
Related companies, and why
- EvozyneSimilar federal contract value in Biotech · null in contracts
- Ajax TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Imbria PharmaceuticalsSimilar federal contract value in Biotech · null in contracts
- Electra TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Caribou BiosciencesSimilar federal contract value in Biotech · null in contracts
- Sirnaomics, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .